Highlights  Ketamine induces mixed effects in animal anxiety tests  Few studies investigated the individual effects of S-ketamine in anxiety/fear tests  None study evaluated the effects of R-Ketamine on anxiety/fear-related behaviors  Systemic ketamine does not affect panic-like behaviors in the elevated T-maze Abstract Ketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, presents rapid and sustained antidepressant effect in clinical and preclinical studies.
There is a widespread discordance among pre-clinical studies addressing the effects of ketamine on anxiety/fear-related behaviors. Additionally, narrative or systematic reviews on ketamine effects in animal tests of anxiety/fear are lacking. In this context, the current study comprehensively reviewed the literature to summarize the effect profile of ketamine on tests of anxiety/fear-related behaviors to improve our understanding about this topic. We found that ketamine effects on anxiety/fear-related behaviors may depend on several factors, as the type of anxiety evoked by the paradigm, schedule of ketamine administration and tested species/sex. Besides that, we also found that the majority of studies evaluated ketamine effects in animal models related to GAD whereas none study evaluated ketamine effects in animal models related to PD.
Based on the aforementioned considerations, another aim of our study was to investigate if ketamine would induce a rapid and sustained anxiolytic and/or panicolytic-like effect in rats exposed to the elevated T-Maze (ETM). The ETM evaluates, in the same animal, conflict-evoked and innate anxiety behaviors which are related, respectively, to GAD and PD (Moreira et al., 2013; Zangrossi Jr and Graeff, 2014) . To this end, we compared the effects of a single injection of ketamine or MK-801 (an NMDA antagonist, also call dizocilpine; Huettner and Bean, 1988; Wong et al., 1986) in the inhibitory avoidance and escape responses generated by the ETM acutely and 24 hours after their administration.
Material and methods

Literature review
We performed a comprehensive literature review to summarize ketamine effects in studies that evaluate anxiety/fear-related defensive behaviors. We performed a preliminary search in the electronic database MEDLINE and found out that some studies that investigated the antidepressant-like effect of ketamine also evaluated its anxiety-related effects as a secondary outcome. Thus, we decide to include, in our search, terms related to depression. Although the post-traumatic stress disorder (PTSD) had been removed from the anxiety disorder category of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), patients' suffering from PTSD frequently exhibit signs of anxiety. Consequently, we also included search terms related to PTSD.
Thus, the studies were searched in the electronic database MEDLINE via the search engine PubMed ® using the following Medical Subject Headings (MeSH ® ) terms as descriptors: (((("Ketamine"[Mesh] ) AND ((((((((((((("Depression"[Mesh] Two independent researchers reviewed the articles at one or more of four levels of detail (title, abstract, full text and a detailed review of experimental design) to determine their eligibility. The inclusion criteria adopted were: (1) administration of ketamine (any dose, route and schedule of treatment) as an intervention group and an appropriated control group; (2) primary behavior data from a test related to anxiety; (3) detailed outcome data (mean, standard error or standard deviation, and sample sizes of both control and intervention groups). Studies that administered ketamine at drinking water or that administered a combination of drugs (including ketamine) to the subjects were excluded.
Regarding item 2 (primary behavior data from a test related to anxiety), we considered all behavioral tests that measure any kind of trace or state anxiety or fear elicited by aversive stimuli (Bourin, 2015; Cryan and Sweeney, 2011; Lezak et al., 2017) . For example, although there is no consensus that the open field test is an animal model of anxiety, many researchers consider that proportion of time or entries in the center of the open field would reflect trace anxiety (Harro, 2018; Prut et al., 2003) . Thus, of the studies that evaluated ketamine effects on the open field, we selected only those studies that reported exploration of the center of the open field. anesthetic doses (80 mg/kg; doses based on Harkin et al., 2003 and pilot studies in our laboratory); MK-801, also known as dizocilpine (Sigma-Aldrich, St. Louis, MO, USA), a non-competitive NMDA antagonist receptor, was administered by i.p. injection at doses of 0.05 and 0.1 mg/kg (Maeng et al., 2008) . All the drugs were freshly dissolved in NaCl 0.9 % (saline). We confirmed that ketamine 80 mg/kg induced anesthesia by checking the lost of tail pinch reflex and pedal withdrawal reflex in the treated animals.
Animals that received the sub-anesthetic doses of ketamine did not exhibit sedation or severe ataxia after administration. The animals from control groups received saline 1 ml/kg by i.p. route.
Behavioral Tests
Elevated T-maze (ETM)
The ETM was derived from the elevated plus maze and was developed by Graeff and colleagues (Zangrossi and Graeff, 1997) to evaluate, in the same apparatus, conflictevoked and fear behaviors. Accordingly, the differences in the experimental setups between the EPM and ETM were mostly procedural. The apparatus consists of 3 arms of equal dimension (50 cm × 10 cm) that were elevated from the floor 50-cm. One of these arms is surrounded by 40-cm high walls and perpendicular to 2 open arms. Three days before the test, rats were handled once a day during 5 minutes to reduce the aversion to the experimenter. Twenty-four hours before the test, the animals were subjected to 30-min confinement in an open arm. This procedure facilitates escape by reducing exploration of the open arms (Teixeira et al., 2000) . On the next day, the acquisition of inhibitory avoidance was assessed by placing the rat at the end of the closed arm and measuring the time that the rat took to leave the closed arm in 3 consecutive trials (baseline, inhibitory avoidance 1 and 2). Escape response was assessed by placing the animal on the extremity of the previously explored open arm and measuring the latency that the animal took to leave this arm in three successive trials (escape 1, escape 2 and escape 3). A cut off time for inhibitory avoidance and escape was 300 s. The experimenter was blind to the pharmacological treatment.
Open field test (OFT)
The arena (open field) consists of a wooden box with 1 m 2 area and 30-cm high walls.
Immediately after the ETM test, the rats were placed in the center of the arena to measure locomotor activity for 5 min. The arena was cleaned with a water-alcohol solution (10%) after each animal was tested. The tests were videorecorded with a webcam that was connected to a computer. Total distance traveled (m) was analyzed by the Anymaze 4.98 path-tracking software (Stoelting, Wood Dale, IL, USA). 
Experimental Design
Statistical analysis
Data analyses were performed using Statistical Package for the Social Sciences SPSS 20.0 software (IBM SPSS Statistics ® , Chicago, IL, USA). The homogeneity of variances was assessed using Levene test. When Levene's test showed that data were not homocedastic, data were log-transformed previously to analyses. Data from ETM (inhibitory avoidance and escape) were analyzed using a two-way repeated measure analysis of variance (ANOVA), with treatment as the independent factor and trials (baseline, avoidance 1-2, and escape 1-3) as the dependent factors. Significant effects of the independent factor or the interaction between the independent and dependent factors were followed by Dunnett post hoc test. Data from the OFT were analyzed by one-way ANOVA followed by Dunnett post hoc test when appropriate. Data from the OFT of experiment that evaluated the anesthetic dose of ketamine were analyzed using unpaired Student's t-test. The significance level was set at p < 0.05. Data were expressed as mean ± SEM.
Results
Literature Review
After applying the MeSH ® words previously described, we found 2038 studies in our literature search. Thus, we applied the filter "Other Animals" to refine our search and found 795 studies. After a check against inclusion and exclusion criteria, we initially selected 51 studies that evaluated ketamine effects in animal tests of anxiety/fear. We excluded 3 studies that evaluated ketamine effects in animals chronically exposed to ethanol. We also excluded 1 study that administered ketamine in drinking water and 2 studies that did not exhibit outcome data (mean and S.E.M.). Table 1 summarizes data extracted from the 45 selected studies. The reporting of details was variable across studies. Fifty five percent of all selected studies were performed in rats, 37 % were performed in mice and only 13 % included females in their evaluation.
The vast majority of studies tested ketamine in adult animals. However, in 8 studies, the age of animals was not reported. These studies described the weight of the animals, from which age cannot be properly identified.
The majority of studies did not report directly which type of ketamine (racemic mixture or isomer) was used. Thus, we searched the grey literature (google search) to identify the type of ketamine based on manufacturer information. In 9 studies we were still unable to identify the type of ketamine. Of the total of selected studies, only 4 evaluated interaction between treatment and trial: F(2.484, 38.505)= 1.456; p= 0.245; Fig. 1 .F] in the ETM nor the locomotor activity in the OFT (F(2, 31)= 1.581; p= 0.222; Table 2 ). Fig. 2B ]. Also, ketamine, at all tested doses, did not impair the locomotor activity in the OFT (F(3, 36)= 1.243; p= 0.309; Table 2 ).
As a single injection of MK-801 0.05 mg/kg acutely impaired inhibitory avoidance in the ETM, we tested if this dose of MK-801 would induce a sustained anxiolytic-like effect. We showed that prior administration of MK-801 0.05 mg/Kg (24 h before the test) did not affect the inhibitory performance [trial effect: F(2, 38)= 17.961 ; p< 0.001; treatment: F(1,19)= 0.316; p= 0.581; interaction between trial and treatment: F(2,38)= 0.366; p= 0.696; Fig. 2C ] and the escape performance [trial effect: F(2, 38)= 1.845 ; p= 0.172; treatment: F(1,19)= 0.123; p= 0.730;
interaction between trial and treatment: F(2,38)= 0.362; p= 0.699; Fig. 2D ] in the ETM test.
Prior administration of MK-801 also did not alter the locomotor activity in the OFT (t(19)= -1.406; p= 0.176, Table 2 ). (Carcone and Ruocco, 2017; Insel et al., 2010) . Each of these domains can be tested by different behavioral paradigms. Most anxiety paradigms used in the studies revised herein are linked to negative affect and involve acute threat (fear), potential threat (anxiety) and sustained threat. Moreover, a common prior intervention adopted in studies investigating anxiety/fear-related behaviors is to submit the subjects to stress conditions. Finally, the sustained antidepressant-like effect of ketamine may be influenced somewhat by stress condition (Polis et al., 2019) . Therefore, we compared the main effects induced by ketamine on the potential threat (anxiety) models (EPM, OFT and LDT) performed in naive versus previously stressed animals. We found a mix of outcomes (anxiolytic, anxiogenic and no effect) that was very similar in both types of conditions (naive versus stressed animals). Given that, besides the type of anxiety paradigm used in the revised studies, other factors may have contributed to the outcome of ketamine on anxiety/fearrelated behaviors. As mentioned in the results section, there are a great variability of dose, number of administration and even interval between administration of ketamine and test exposure.
Regarding published studies involving acute or sustained threat (fear), about half of them reported an anxiolytic-like effect of ketamine in behavioral responses such as freezing. In contrast, all the 3 experiments that evaluated social interaction as a consequence of acute or sustained stress reported an anxiogenic-like effect of ketamine. Noteworthy, most of these studies did not evaluate ketamine effects considering resilient versus stress-vulnerable animals. As proposed by Musazzi and coworkers (Musazzi et al., 2018) , investigate ketamine effects on resilient versus stress-vulnerable animals could increase accuracy of results.
In general, paradigms of acute or sustained threat have been related to PTSD (Frandreau and Toth, 2017) . There are few studies that evaluated ketamine effects on patients diagnosed with PTSD or with symptoms of PTSD (Banov et al., 2019; Liriano et al., 2019) . Although some of these studies have shown that ketamine may be an option for PTSD treatment (Albott et al., 2018; Feder et al., 2014) , other studies described possible side effects of ketamine that could worsen PTSD symptoms (Schönenberg et al., 2008 (Schönenberg et al., , 2005 . Of note, this last study mentioned found that accident victims treated with S-ketamine exhibited greater symptoms of dissociation, re-experiencing and avoidance than those treated with racemic ketamine (Schönenberg et al., 2005) . On the other hand, depressed patients with a history of PTSD who received a single racemic ketamine infusion did not experience a clinically significant increase in dissociative or anxiety symptoms (Zeng et al., 2013) . These conflicting and pending results highlight the need for further studies comparing S-ketamine and R-ketamine in preclinical protocols of acute threat as well as in patients diagnosed with PTSD with and without comorbidities, such as depression.
In contrast, from the 12 experiments that evaluated ketamine effects on NSF, 11 reported an anxiolytic-like effect of ketamine and only 1 report no effect. The NSF is based on the inhibition of feeding behavior generally caused by a novel environment (Blasco-Serra et al., 2017) . The NSF has been considered an animal model of anxiety since it measures a conflict between the anxiogenic environment and hunger-induced behavior, which is sensitive to anxiolytic drugs (Cryan and Sweeney, 2011; Dulawa and Hen, 2005; Merali et al., 2003; Shephard and Broadhurst, 1982) . On the other hand, some authors suggest that NSF could be an animal model of depression by assessing anhedonia and detecting the effects of chronic, but not acute treatment with antidepressant drugs (Dulawa and Hen, 2005; Nestler and Hyman, 2010; Powell et al., 2012) . Thus, one possibility is that the test assesses antidepressant drug effects by detecting their anxiolytic effects (Ramaker and Dulawa, 2017) .
Within this context, many of the selected studies by the present review reported the effect of ketamine on NSF as a fast-acting antidepressant-like effect. Of note, some of the selected studies reported that ketamine had no effect on distinct anxiety-like behaviors (Autry et al., 2011; Brachman et al., 2016; Carrier and Kabbaj, 2013; Pham et al., 2017) while others reported that ketamine had an antidepressant-like effect in distinct depression-like behaviors (Li et al., 2010; Lin et al., 2016; Soumier et al., 2016; Zanos et al., 2015) . In this way, the total data set on the NSF is most consistent with an antidepressant-like effect of ketamine rather than an anxiolytic-like effect.
The direction of ketamine effects on anxiety/fear-related behaviors might also be influenced by the so-called publication bias. There is some evidence suggesting that negative results are underreported/unpublished (Driessen et al., 2015; Mlinarić et al., 2017) . In fact, the risk of publication bias in both, pre-clinical (Mohammad et al., 2016) and clinical studies (Turner et al., 2008) , have already been identified. Therefore, there is much space to improve preclinical research and reduce the risk of bias. For example, a good practice is to register, in advance, the protocols and experimental design of projects in online repositories such as www.preclinicaltrials.eu, to reduce risk of bias (Jansen et al., 2014; Tillmann, 2017) .
The vast majority of the revised articles did not consider gender differences in their experiments. Although is not completely understood whether ketamine has sex-specific effects (Chang et al., 2018; Herzog et al., 2019) , some evidence suggests more pronounced biochemical and behavioral effects of ketamine in females (Carrier and Kabbaj, 2013; Dossat et al., 2018; Franceschelli et al., 2015; Guarraci et al., 2018; Saland and Kabbaj, 2018; Thelen et al., 2019 Thelen et al., , 2016 . It is noteworthy that women are twice more likely than men to experience an anxiety disorder over their lifespan (Bandelow and Michaelis, 2015; Craske et al., 2017; Hantsoo and Epperson, 2017; Remes et al., 2016) . Altogether, these data highlight the importance of filling this gap, which means to produce further evaluation of ketamine effects on anxiety/fear-related behavior in females.
Regarding the quality of the selected studies, some points deserve to be mentioned. Ketamine is a chiral anesthetic drug that is usually marketed as a racemic mixture containing equal amounts of two enantiomers, S-and R-ketamine. Meanwhile, pharmacokinetic and pharmacodynamic differences between the ketamine enantiomers have been described . For instance, S-ketamine has about a 2-4-fold greater affinity for the NMDA and opioid receptors, higher anesthetic potency and maybe fewer adverse effects than R-ketamine (Andrade, 2017; Domino, 2010; Kohrs and Durieux, 1998; Muller et al., 2016; White et al., 1980) . In constrast, R-ketamine seems to have a longer lasting antidepressantlike effect than S-ketamine possibly mediated by different molecular mechanisms (Fukumoto et al., 2017; Yang et al., 2018 Yang et al., , 2015 Zhang et al., 2014) . Surprisingly, most of the selected studies in this review were inaccurate in identifying the type of ketamine that was used and some of them did not even describe the manufacturer. Additionally, in our review, in 3 of the studies that specifically investigated the effects of S-ketamine on anxiety/fear-related behaviors, 2 identified an anxiogenic-like effect of the drug. From this, it is important that future studies reduce the risk of bias by clearly describing the type of ketamine used and its manufacturer. Also, future studies should address specifically the effects of different enantiomers of ketamine on anxiety/fear-related behaviors.
Another issue about the quality of the selected studies is the absence of detailed information about the interval between ketamine administration and behavioral evaluation. This observation is in line with previous evidence suggesting that the majority of publications fail to include key information (Avey et al., 2016; Kilkenny et al., 2009; Macleod et al., 2015) .
Inaccurate or incomplete reporting has potential scientific, ethical, and economic implications. Collectively, these data strengthen the importance of following guidelines such as those of PREPARE (Planning Research and Experimental Procedures on Animals:
Recommendations for Excellence) (Smith et al., 2018) and ARRIVE (Animals in Research:
Reporting In Vivo Experiments) (Kilkenny et al., 2010; Percie et al., 2019) initiative to increase reproducibility and to reduce publication bias in pre-clinical studies.
Finally, it is important to mention some limitations of our review. We limited our search to the electronic database PubMed and to English-language published data. We also did not perform a meta-analysis of the data.
New findings
From the evidence gathered in our review, we identified an important gap in the literature regarding ketamine effects in fear-related behaviors associated to PD. Therefore, we evaluated the effect of ketamine in an animal model related to PD. Overall, we found that: 1) racemic ketamine, at sub-anesthetic and anesthesic doses, did not induce acute and/or sustained anxiolytic/panicolytic-like effects in rats exposed to the ETM; 2) MK-801, another non-competitive NMDA receptor antagonist, induced an acute, but not sustained anxiolyticlike effect in rats exposed to the ETM. The reported effects do not seem to be due to locomotor activity changes, as both drugs, at any administered dose and interval of evaluation, did not influence open field performance. Despite this, the anesthetic dose of ketamine increased baseline latency during inhibitory avoidance, suggesting at least a residual depressor effect.
The lack of ketamine effects on the ETM rats performance, acutely or 24 h after its administration, reinforces the controversial findings reported in previous studies, as described in table 1. For example, anesthetic doses of ketamine induced anxiolytic-like (Hayase et al., 2006) , anxiogenic-like (Morena et al., 2017) or no effect (Magalhaes et al., 2017) in different tests of anxiety. Regarding sub-anesthetic doses of ketamine, similar mix of outcomes has been previously reported (as detailed in Table 1 ). Although the reasons for these discrepant results are unknown, they may be attributed to differences in the behavioral paradigms, animal species and interval between ketamine treatment and test. For instance, the genetic background of a strain is among the several factors that may affect the behavioral responses of the animals to a drug Võikar et al., 2001) . Ketamine 30 mg/kg produced an anxiolytic-like effect on male ICR mice (Hayase et al., 2006 ) and no effect on male 129S6/SvEvTac mice (Brachman et al., 2016) submitted to the EPM. Ketamine 10 mg/kg induced an anxiolytic-like effect in NSF, but did not alter the behavior in the EPM and in the context and cued fear conditioning (Autry et al., 2011) . One possible explanation is that different animal models of anxiety can recruit distinct neural substrates and, therefore, produce contradictory results.
We also cannot exclude that ketamine effects on anxiety-like behaviors are influenced by the ketamine enantiomer. As described in the previous section, S-and R-ketamine have different neurochemical and behavioural effects and in the present study, we evaluated a racemic mixture of ketamine on behavioral tests. Thus, we cannot exclude the possibility that an specific enantiomer of ketamine has a potential panicolytic-like effect.
Noteworthy, the lowest tested dose of MK-801, a highly selective NMDA receptor antagonist (Wong et al., 1986) , impaired inhibitory avoidance, but not escape behavior, suggesting an acute anxiolytic-like effect. This result is in agreement with results observed in other studies that evaluated the effect of MK-801 in animal models of anxiety (Adamec et al., 1998; Engin et al., 2009; Karcz-Kubicha et al., 1997; Refsgaard et al., 2017) . Additionally, the anxiolyticlike effect of MK-801 was not sustained, as it was not detected 24 h later. This absence of sustained effect of MK-801 in the ETM is consistent with the absence of sustained effects in the EPM (Hill et al., 2015) and in the forced swimming test (Autry et al., 2011) .
One speculative explanation for the contradictory effects of ketamine and MK-801, both NMDA receptor antagonists, is that ketamine, different from MK-801, is a multimodal-acting drug. Ketamine and its active metabolites can act beyond the NMDA receptor, several other targets such as opioid and serotonergic receptors, calcium, sodium and chloride channels, 5-HT transporter, among others (du Jardin et al., 2016; Kapur and Seeman, 2001; Salat et al., 2015) . In this sense, it is possible that ketamine and its metabolites could act on different types of receptors with opposite transduction mechanisms that would prevent the appearance of an anxiolytic-like effect.
Another possibility is a differential modulation of glutamate release by ketamine and MK-801 in the prefrontal cortex. Systemic ketamine administration (10-30 mg/kg) may increase extracellular glutamate levels in the prefrontal cortex (Lorrain et al., 2003; Moghaddam et al., 1997) , which may shift the balance between AMPA-to-NMDA receptors-mediated neurotransmission and contribute to the antidepressant-like effect of ketamine (Maeng et al., 2008; Zanos and Gould, 2018) . Additionally, there is some evidence that the activation of AMPA receptors could increase anxiety (Alt et al., 2006; Andreasen et al., 2015; Fitzpatrick et al., 2016) . Under these circumstances, it is possible that the activation of AMPA receptors mediated by increased ketamine induced-glutamate neurotransmission would increase anxiety, an effect that would counteract the possible anxiolytic-like effect of ketamine mediated by blocking the NMDA receptors. On the other hand, MK-801 increased extracellular glutamate levels in the prefrontal cortex only at high doses (0.3-0.6 mg/kg) (Roenker et al., 2012; Zuo et al., 2006) . Consequently, a very low dose of MK-801 like the one used in our study (0.05 mg/kg) probably did not increase glutamate levels, which resulted in an anxiolytic-like effect mediated by the exclusive NMDA receptors blockade. This hypothesis, however, warrants further investigation and it is beyond the scope of the present study.
Meanwhile, a limitation of our study is that we evaluated ketamine and MK-801 effects only in one animal model related to PD. Given that, future studies should evaluate ketamine and MK-801 effects in other animal models of panic, such as the electrical stimulation of the dorsal periaqueductal grey matter (Moreira et al., 2013; Schenberg et al., 2001) .
In summary, the present study provided an overview on the current state of knowledge about ketamine effects on anxiety/fear-related behaviors. At the same time, sub-anesthesic and anesthesic doses of ketamine had no effect on anxiety or panic-related behaviors in the ETM.
The individual effects of R-ketamine and S-ketamine on anxiety/fear-related behaviors, including sex differences, should be further addressed.
